Glutathione S-Transferases in Helminths

Смирнов, Л. П.; Борвинская, Екатерина Витальевна; Kochneva, Albina; Borvinskaya, Ekaterina; Koshneva, Al’bina; Sukhovskaya, Irina

doi:10.17076/eb213

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…У нематод НТЗ ингибирует глутатион-S-трансферазуосновной фермент детоксикации, в результате чего эти организмы теряют устойчивость к некоторым лекарственным препаратам и защитным факторам иммунитета человека [13,23], а также модулирует ген Avr-14, кодирующий субъединицу альфа-типа глутамат-управляемого хлоридионного канала, в результате чего образуются субстраты для противопаразитарных препаратов семейства авермектинов, что повышает их эффективность. Авермектины, в свою очередь, усиливают воздействие глутамата на специфичные для беспозвоночных ионные каналы, вызывая гиперполяризацию, приводящую к параличу нервно-мышечных систем беспозвоночных [13,24,25].…”

Section: противогельминтная активностьunclassified

Pharmacological efficacy and potential of the use of nitazoxanide, a thiazolide drug with a wide spectrum of action

Rusanovsky,

Savelyeva,

Tadtaeva

et al. 2024

Rev Clin Pharm Drug Ther

View full text Add to dashboard Cite

The article is devoted to the possibility and prospects of using nitazoxanide in a wide range of diseases. Based on literature data, the authors evaluate the pharmacological effectiveness and substantiate the potential of using nitazoxanide in bacterial, helminthic, protean, viral and oncological diseases. This information is of interest and can be used to decide on the need to conduct clinical trials of nitazoxanide in Russia. The goal is to evaluate the pharmacological activity and potential of nitazoxanide in bacterial, helminthic, protean, viral and oncological diseases. Materials and methods: A systematic search for current information was conducted in four databases until December 1, 2023: PubMed, EMBASE, Web of Science and Cochrane Library. Work included preclinical studies in vitro and in vivo, as well as randomized clinical trials comparing the pharmacological effectiveness of nitazoxanide and placebo. Conclusions: the broad-spectrum thiazolide drug nitazoxanide has antibacterial, antiprotozoal, anthelmintic, antiviral and antitumor activity. This is achieved through its pharmacological properties, namely: regulation of the cell cycle, apoptosis, cell proliferation and migration; activation of innate immunity; influence on the synthesis and activation of cell proteins, some of which are links in cellular signaling pathways; binding to proteins of viruses, bacteria, protozoa and helminths with disruption of their vital functions; immunomodulating effect by regulating the activity of pro- and anti-inflammatory cytokines. The article systematizes and summarizes current information on the pharmacodynamics of NTZ, as well as the results of preclinical and clinical studies of the drug, and discusses further prospects.

show abstract

Section: противогельминтная активностьunclassified